0001376339-15-000089.txt : 20151019 0001376339-15-000089.hdr.sgml : 20151019 20151019091920 ACCESSION NUMBER: 0001376339-15-000089 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151016 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20151019 DATE AS OF CHANGE: 20151019 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIMEDX GROUP, INC. CENTRAL INDEX KEY: 0001376339 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 900300868 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35887 FILM NUMBER: 151163115 BUSINESS ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 BUSINESS PHONE: 678-384-6720 MAIL ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 FORMER COMPANY: FORMER CONFORMED NAME: Alynx, Co. DATE OF NAME CHANGE: 20060922 8-K 1 a8-k1016.htm 8-K 8-K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934
 
Date of Report (date of earliest event reported): October 19, 2015
 
MIMEDX GROUP, INC.
(Exact name of registrant as specified in charter)
 
Florida
(State or other jurisdiction of incorporation)
 
001-35887
(Commission File Number)
 
26-2792552
(IRS Employer Identification No.)
 
1775 West Oak Commons Ct, NE
Marietta, GA
(Address of principal executive offices)
 
30062
(Zip Code)
 
(770) 651-9100
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 7.01
Regulation FD Disclosure

The Board of Directors of MiMedx Group, Inc. (the "Company") has authorized an increase of $10 million to the Company’s Share Repurchase Program. This increases the total authorized to $40 million since the program commenced on May 12, 2014. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the Share Repurchase Program at any time.



 
 



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated:
October 19, 2015
MIMEDX GROUP, INC.
 
 
 
 
 
 
 
 
 
 
 
By:
/s/: Michael J. Senken
 
 
 
 
Michael J. Senken, Chief Financial Officer